Skip to main content
. Author manuscript; available in PMC: 2017 Nov 13.
Published in final edited form as: Cell Transplant. 2016 Nov;25(11):1967–1977. doi: 10.3727/096368916X691457

Figure 1.

Figure 1

Efavirenz (EFV) reduces proliferation of neural stem cells (NSCs). EFV reduces proliferation of NSCs by MTT assay. (A) NSCs were treated with a series of concentrations of EFV, vehicle control (ctrl), and H2O2 (positive control; 100 μM) for 24 h. Data are presented as a percentage of EFV treatment over ctrl. Each bar is presented as mean ± SEM (*p < 0.05; ***p < 0.001). (B) EFV inhibits bromodeoxyuridine (BrdU) incorporation into NSCs as evidenced by immunocytochemistry: After treatment consisting of 5 μM of EFV or vehicle control (ctrl) for 24 h, and incubation with BrdU (10 μM) for 2 h, NSCs were fluorescence stained with BrdU (green) and nestin (red). Staining of control treatment is shown in (a) BrdU, (b) nestin, and (c) merged; EFV treatment in (d) BrdU, (e) nestin, and (f) merged. Scale bars: 20 μm (a–f). (g) Quantified data are expressed as the percentage of double-labeled cells. Data are presented as mean ± SEM (***p < 0.001).